Testing HRS-1358 for breast cancer that has spread
Treatments studied
Part of Cancer, Skin clinical trials.
This early-phase study tests HRS-1358 tablets in people with breast cancer that is locally advanced or has spread. It may help learn whether the drug can control cancer, while also checking safety and how the body handles it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer that is either locally advanced or metastatic (has spread) confirmed by biopsy/pathology
- You are postmenopausal, or if you are not, you must be on ovarian suppression
- You have already tried at least one type of hormone (endocrine) treatment for the advanced/metastatic stage
- Your general health is good, with an ECOG score of 0 or 1 (able to do most daily activities)
- You have acceptable blood/organ function based on lab tests your team will review
- You can read/understand the study and sign consent in writing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HRS-6209 combined with other treatments for people with breast cancer that has worsened after previous therapy. It aims to find a more effective way to control the cancer.
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
This early study (Phase 1) tests whether HRS-1167 can be given safely to people with advanced solid tumors. It also looks for early signs of activity, especially in cancers with HRR gene mutations (like ovarian, breast, pancreatic, and prostate cancers).
This trial tests a new combination of two drugs (HRS-8080 and Dalpiciclib) for women with advanced breast cancer that cannot be removed by surgery. It may be an option if you have already tried hormone therapy or are starting advanced treatment for the first time.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.